|
FGFR1OP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.81239484426033E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.32379671061267E-11 |
| Normal-vs-Stage2 |
5.44689848780422E-11 |
| Normal-vs-Stage3 |
1.79178893944254E-12 |
| Normal-vs-Stage4 |
5.65192337376175E-12 |
| Stage1-vs-Stage2 |
4.989600E-01 |
| Stage1-vs-Stage3 |
1.366450E-02 |
| Stage1-vs-Stage4 |
2.426200E-01 |
| Stage2-vs-Stage3 |
2.822600E-01 |
| Stage2-vs-Stage4 |
7.041600E-01 |
| Stage3-vs-Stage4 |
4.897200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.51194637207664E-12 |
| Normal-vs-AfricanAmerican |
8.84019999980445E-07 |
| Normal-vs-Asian |
1.1970000546313E-09 |
| Caucasian-vs-AfricanAmerican |
1.108160E-01 |
| Caucasian-vs-Asian |
2.679200E-01 |
| AfricanAmerican-vs-Asian |
5.091800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.879563750952E-13 |
| Normal-vs-Female |
8.04989408464962E-12 |
| Male-vs-Female |
1.808020E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.48190365428991E-11 |
| Normal-vs-Age(41-60Yrs) |
6.69941879749558E-12 |
| Normal-vs-Age(61-80Yrs) |
2.65076849359502E-12 |
| Normal-vs-Age(81-100Yrs) |
8.89029999617819E-08 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.137600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.301500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.288200E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.339800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.760950E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.840790E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.479500E-03 |
| Classical-VS-Follicular |
2.995200E-01 |
| Classical-VS-Other |
3.658000E-01 |
| Classical-VS-Normal |
2.23420171252542E-11 |
| Tall-VS-Follicular |
9.403800E-04 |
| Tall-VS-Other |
1.521740E-02 |
| Tall-VS-Normal |
1.66333613549341E-12 |
| Follicular-VS-Other |
7.352800E-01 |
| Follicular-VS-Normal |
1.97119998102124E-09 |
| Other-VS-Normal |
1.231820E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.69022606811131E-12 |
| Normal-vs-N1 |
4.31088498231702E-12 |
| N0-vs-N1 |
4.817400E-01 |
|
|
